Get the Stockscreener App
6.44
0.31%
0.02
Silence Therapeutics Plc Adr stock is traded at $6.44, with a volume of 92,633.
It is up +0.31% in the last 24 hours and up +22.90% over the past month.
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
See More
Previous Close:
$6.42
Open:
$6.39
24h Volume:
92,633
Relative Volume:
0.46
Market Cap:
$243.24M
Revenue:
$31.37M
Net Income/Loss:
$-53.77M
P/E Ratio:
-4.4301
EPS:
-1.4537
Net Cash Flow:
$-49.02M
1W Performance:
+16.67%
1M Performance:
+22.90%
6M Performance:
+7.51%
1Y Performance:
-69.58%
1-Day Range:
$6.01
$6.5399
1-Week Range:
$5.33
$6.55
52-Week Range:
$1.97
$22.46
Silence Therapeutics Plc Adr Stock (SLN) Company Profile
Name
Silence Therapeutics Plc Adr
Sector
Industry
Phone
44-0-20-3457 6900
Address
72 HAMMERSMITH ROAD, LONDON
Compare SLN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SLN
Silence Therapeutics Plc Adr
|
6.44 | 243.24M | 31.37M | -53.77M | -49.02M | -1.4537 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.85 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.94 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.24 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
250.30 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Silence Therapeutics Plc Adr Stock (SLN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-11-25 | Initiated | Goldman | Sell |
| Dec-02-24 | Reiterated | BMO Capital Markets | Outperform |
| Sep-03-24 | Initiated | Jefferies | Buy |
| Jan-31-24 | Initiated | BMO Capital Markets | Outperform |
Silence Therapeutics Plc Adr Stock (SLN) Latest News
H.C. Wainwright reiterates buy rating on Silence Therapeutics stock By Investing.com - Investing.com South Africa
Wall Street Analysts Think Silence Therapeutics (SLN) Could Surge 556.19%: Read This Before Placing a Bet - MSN
Silence Therapeutics’s SWOT analysis: gene therapy stock faces pivotal year By Investing.com - Investing.com India
Silence Therapeutics’s SWOT analysis: gene therapy stock faces pivotal year - Investing.com
Wall Street Analysts Believe Silence Therapeutics (SLN) Could Rally 590.66%: Here's is How to Trade - MSN
Silence Therapeutics stock hits 52-week low at $3.19 By Investing.com - Investing.com South Africa
Silence Therapeutics stock hits 52-week low at $3.19 - Investing.com
Silence Therapeutics (SLN) Upgraded to Buy: Here's What You Should Know - MSN
Silence Therapeutics stock hits 52-week low at $3.66 amid downturn - Investing.com
Silence Therapeutics stock hits 52-week low at $3.66 amid downturn By Investing.com - Investing.com South Africa
Taiwan Semiconductor Valuation: How Realistic Is the Price? - The Globe and Mail
Silence Therapeutics stock hits 52-week low at $4.04 amid challenges - Investing.com
Silence Therapeutics stock hits 52-week low at $4.04 amid challenges By Investing.com - Investing.com South Africa
Earnings call transcript: Silence Therapeutics sees stock rise post-earnings - Investing.com
BESREMi Achieves Strong Market Growth Amid Rising Demand for Polycythemia Vera Treatment - GlobeNewswire Inc.
Goldman Sachs cuts Silence Therapeutics stock rating to Sell By Investing.com - Investing.com South Africa
Should investors be concerned about Silence Therapeutics Plc ADR (SLN)? - US Post News
Akoya Biosciences Inc (AKYA)’s Day in Review: Closing at 2.34, Down by -4.88 - The Dwinnex
Cloudflare Inc’s (NET) Stock: A 29.10% Simple Moving Average for the Past 20 Days - The News Heater
Silence Therapeutics's SWOT analysis: stock poised for growth amid challenges By Investing.com - Investing.com South Africa
Silence Therapeutics's SWOT analysis: stock poised for growth amid challenges - Investing.com
H.C. WAINWRIGHT MAINTAINS $75 TARGET ON SILENCE THERAPEUTICS STOCK By Investing.com - Investing.com South Africa
European Equities Traded in US as American Depositary Receipts Surge on Monday - MSN
Top 3 Health Care Stocks That May Explode In Q4 - Benzinga
Silence Therapeutics' SWOT analysis: stock's potential in RNAi therapeutics - Investing.com
SLN Stock Down Despite Cholesterol Drug Lowering Lipoprotein Levels - Yahoo Finance
Top 3 Health Care Stocks You'll Regret Missing In Q4Amarin Corp (NASDAQ:AMRN) - Benzinga
Zerlasiran shows promise in phase 2 study for cardiovascular risk - Investing.com India
Silence Therapeutics to Join Guggenheim Biotech Conference By Investing.com - Investing.com India
Here's Why Momentum in Silence Therapeutics PLC Sponsored ADR (SLN) Should Keep going - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
BioCryst (BCRX) Surges 9.9%: Is This an Indication of Further Gains? - Nasdaq
Claire Keast-Butler - Cooley
Our approach to nucleotide-based therapeutics - AstraZeneca
5 Stocks to Buy as the Drug Industry Bets Big on Innovation - Nasdaq
Silence Therapeutics PLC Sponsored ADR (SLN) Upgraded to Strong Buy: What Does It Mean for the Stock? - Yahoo Finance
Genfit (NASDAQ:GNFT) Stock Quotes, Forecast and News Summary - Benzinga
Silence Therapeutics (SLN) Stock Price, News & Analysis - MarketBeat
Silence Therapeutics (SLN) - Zacks Investment Research
Silence Therapeutics Plc Adr Stock (SLN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.10%
1.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):